Гуселькумаб в терапии больных бляшечным псориазом средней и тяжелой степени тяжести: эффективность и безопасность блокады интерлейкина-23

Обложка


Цитировать

Полный текст

Аннотация

Материал и методы. Представлен обзор литературы, в котором рассматривается значение интерлейкина-(ИЛ)-23 в патогенезе бляшечного псориаза и анализируются результаты клинических исследований 1-й и 2-й фаз, а также сравнительных исследований 3-й фазы VOYAGE 1, VOYAGE 2, NAVIGATE и ECLIPSE, в которых оценивалась эффективность и безопасность блокатора субъединицы p19 ИЛ-23 гуселькумаба. Для подготовки обзора были использованы базы данных научной литературы PubMed и РИНЦ.
Результаты. Продемонстрирована высокая эффективность и безопасность гуселькумаба в терапии больных бляшечным псориазом. Значение PASI 90 на 16-й неделе терапии гуселькумабом достигало 73,3 %, на 24-й неделе лечения — 80,2 % (исследование VOYAGE 1). При продолжении лечения в течение 48 недель терапевтический эффект сохранялся. Показана высокая эффективность терапии гуселькумабом больных, у которых ранее была неэффективной терапия другими генноинженерными биологическими препаратами. В сравнительных исследованиях показана более высокая терапевтическая эффективность гуселькумаба по сравнению с блокаторами ФНО-α, субъединицы p40 ИЛ-12/23, ИЛ-17. Частота развития нежелательных явлений во время терапии гуселькумабом и другими биологическими препаратами, использовавшимися в сравнительных исследованиях, была невысокой и сопоставимой.
Заключение: блокатор субъединицы p19 ИЛ-23 гуселькумаб представляет собой эффективное и безопасное средство для лечения больных бляшечным псориазом средней и тяжелой степени тяжести.

Об авторах

В. В. Чикин

Государственный научный центр дерматовенерологии и косметологии Министерства здравоохранения Российской Федерации

Автор, ответственный за переписку.
Email: chikin@cnikvi.ru

д.м.н., ведущий научный сотрудник отдела дерматологии 

107076, Российская Федерация, г. Москва, ул. Короленко, д. 3, стр. 6

Россия

Список литературы

  1. Helmick C. G., Lee-Han H., Hirsch S. C. et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45.
  2. Бакулев А. Л., Фитилева Т. В., Новодережкина Е. А. и др. Псориаз: клинико-эпидемиологические особенности и вопросы терапии. Результаты опроса пациентов и врачей, проведенного в медицинских организациях в России. Вестник дерматологии и венерологии. 2018;94(3):67–76.
  3. Кубанов А. А., Богданова Е. В. Организация и результаты оказания медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Итоги 2018 года. Вестник дерматологии и венерологии. 2019;95(4):8–23.
  4. Khawaja A. R., Bokhari S. M., Tariq R. et al. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim. Care Companion CNS Disord. 2015;17(3). doi: 10.4088/PCC.14m01629
  5. Mattei P. L., Corey K. C., Kimball A. B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337.
  6. Barankin B., DeKoven J. Psychosocial effect of common skin diseases. Can Fam Physician. 2002;48:712–716.
  7. Kimball A. B., Jacobson C., Weiss S. et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.
  8. Basavaraj K. H., Navya M. A., Rashmi R. Relevance of psychiatry in dermatology: present concepts. Indian J Psychiatry. 2010;52(3):270–275.
  9. Vardy D., Besser A., Amir M. et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002;147(4):736–742.
  10. Schmid-Ott G. Future trends in psychodermatological psoriasis research: somatopsychic or psychosomatic focus? Dermatol Psychosom. 2003;4(3):129–130.
  11. Schmid-Ott G., Künsebeck H. W., Jäger B. et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta DermVenereol. 2005;85(1):27–32.
  12. Schmid-Ott G., Schallmayer S., Calliess I. T. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25(6):547–554.
  13. Kurd S. K., Troxel A. B., Crits-Christoph P. et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
  14. Weiss S. C., Kimball A. B., Liewehr D. J. et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512–518.
  15. Mattoo S. K., Handa S., Kaur I. et al. Psychiatric morbidity in psoriasis: prevalence and correlates in India. Ger J Psychiatry. 2005;8:17–22.
  16. Russo P. A., Ilchef R., Cooper A. J. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155–159. Quiz 160–161.
  17. Sharma S., Bassi R., Singh A. A comparative study of depression and anxiety in psoriasis and other chronic skin diseases. J Pakistan Assoc Dermatologists. 2011;21(4):235–240.
  18. Kimball A.B., Gladman D., Gelfand J. M. et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042.
  19. Oliveira M. F., Rocha B. O., Duarte G. V. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
  20. Langan S. M., Seminara N. M., Shin D. B. et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562.
  21. Takeshita J., Grewal S., Langan S. M. et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol. 2017;76:393–403.
  22. Takeshita J., Grewal S., Langan S. M. et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–390.
  23. Gelfand J. M., Troxel A. B., Lewis J. D. et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–1499.
  24. Armstrong E. J., Harskamp C. T., Armstrong A. W. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
  25. Samarasekera E. J., Neilson J. M., Warren R. B. et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346.
  26. Abuabara K., Azfar R. S., Shin D. B. et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–592.
  27. Svedbom A., Dalen J., Mamolo C. et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta DermVenereol. 2015;95(7):809–815.
  28. Lew W., Bowcock A. M., Krueger J. G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. Trends Immunol. 2004;25:295–305.
  29. Austin L. M., Ozawa M., Kikuchi T. et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752–759.
  30. Yawalkar N., Karlen S., Hunger R. et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111:1053–1057.
  31. Brembilla N. C., Senra L., Boehncke W.-H., The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018 Aug 2;9:1682.
  32. Lin A. M., Rubin C. J., Khandpur R. et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500.
  33. Schön M. P., Erpenbeck L. The Interleukin-23/Interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018 Jun 15;9:1323.
  34. Lowes M. A., Kikuchi T., Fuentes-Duculan J. et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–1211.
  35. Haider A. S., Lowes M. A., Suarez-Farinas M. et al. Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol. 2008;180:1913–1920.
  36. Lowes M. A., Russell C. B., Martin D. A. et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34:174–181.
  37. Zaba L. C., Cardinale I., Gilleaudeau P. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194.
  38. Kryczek I., Bruce A.T., Gudjonsson J. E. et al. Induction of IL-171 T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733–4741.
  39. Kagami S., Rizzo H. L., Lee J. J. et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373–1383.
  40. Zhang L., Yang X. Q., Cheng J. et al. Increased Th17 cells are accompanied by FoxP3(1) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108–117.
  41. Hawkes J. E., Chan T. C., Krueger J. G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
  42. Hawkes J. E., Yan B. Y., Chan T. C., Krueger J. G. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613.
  43. Bettelli E., Oukka M., Kuchroo V. K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345–350.
  44. Raychaudhuri S. P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–193.
  45. Wang X., Wei Y., Xiao H. et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol. 2016;46(6):1343–1350.
  46. Vignali D. A., Kuchroo V. K. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722–728.
  47. Oppmann B., Lesley R., Blom B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725.
  48. Krueger J. G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30–36.
  49. Nograles K. E., Davidovici B., Krueger J. G. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg. 2010;29:3–9.
  50. Yawalkar N., Tscharner G. G., Hunger R. E., Hassan A.S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci. 2009;54:99–105.
  51. Gordon K. B., Duffin K. C., Bissonnette R. et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–144.
  52. di Cesare A., di Meglio P., Nestle F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
  53. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900–911.
  54. Zúñiga L. A., Jain R., Haines C., Cua D. J. Th17 cell development: from the cradle to the grave. Immunol Rev. 2013;252(1):78–88.
  55. Gaffen S. L., Jain R., Garg A. V., Cua D. J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.
  56. Aggarwal S., Ghilardi N., Xie M. H. et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910–1914.
  57. Ferber I. A., Brocke S., Taylor-Edwards C. et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156:5–7.
  58. Langrish C. L., Chen Y., Blumenschein W. M. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–240.
  59. Chan T. C., Hawkes J. E., Krueger J. G. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119.
  60. Yang L., Li B., Dang E. et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci. 2016;81(2):85–92.
  61. Bovenschen H. J., van de Kerkhof P. C., van Erp P. E. et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853–1860.
  62. Lee E., Trepicchio W. L., Oestreicher J. L. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–130.
  63. Michalak-Stoma A., Bartosińska J., Kowal M. et al. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers. 2013;35(6):625–631.
  64. Lupardus P. J., Garcia K. C. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol. 2008;382(4):931–941.
  65. Chan J. R., Blumenschein W., Murphy E. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577–2587.
  66. Piskin G., Sylva-Steenland R. M., Bos J. D., Teunissen M. B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–1915.
  67. Kulig P., Musiol S., Freiberger S. N. et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016 Nov 28;7:13466.
  68. Sofen H., Smith S., Matheson R. T. et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040.
  69. Mylle S., Grine L., Speeckaert R. et al. Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly. Am J Clin Dermatol. 2018;19(5):625–637.
  70. Gooderham M. J., Papp K. A., Lynde C. W. Shifting the focus — the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119.
  71. Blauvelt A., Papp K. A., Griffiths C. E. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–417.
  72. Reich K., Armstrong A. W., Foley P. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–431.
  73. Langley R. G., Tsai T.-F., Flavin S. et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114–123.
  74. Ohtsuki M., Kubo H., Morishima H. et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45:1053–1062.
  75. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019;15(6):589–597.
  76. Reich K., Armstrong A. W., Langley R. W. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839.
  77. Foley P., Gordon K., Griffiths C. E. et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154:676–683.
  78. Hu C., Yao Z., Chen Y. et al. A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. J Pharmacokinet Pharmacodyn. 2018;45:523–535.
  79. Griffiths C. E., Radtke M. A., Youn S. W. Clinical Response after Guselkumab Treatment among Adalimumab PASI 90 Non-responders: Results from the VOYAGE 1 and 2 Trials. Poster P6858 presented at EADV Congress 2019, Madrid.
  80. Griffiths C. E., Papp K. A., Song M. et al. Maintenance of response with guselkumab for up to 3 years’ treatment in the phase 3 VOYAGE 1 trial of patients with plaque psoriasis. SKIN The Journal of Cutaneous Medicine. 2018;2:S90. https://jofskin.org/index.php/skin/article/view/487 (accessed 16.12.2019).
  81. Gordon K. B., Armstrong A. W., Foley P. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019;139(12):2437–2446.
  82. Reich K., Papp K. A., Armstrong A. W. et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039–1049.
  83. Wechter T., Cline A., Feldman S. R. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag. 2018;14:1489–1497.
  84. Al-Salama Z. T., Scott L. J. Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2018;19:907–918.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Чикин В.В., 2019

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах